Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

396 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Expanded access protocol (EAP) program for access to investigational products for amyotrophic lateral sclerosis (ALS).
Yerton M, Winter A, Gelevski D, Addy G, Kostov A, Lieberman C, Weber H, Doyle M, Kane G, Cohen C, Parikh N, Burke KM, Rohrer M, Stirrat T, Bruno M, Hochman A, Luppino S, Scalia J, D'Agostino D, Sinani E, Yu H, Drake K, Hagar J, Sherman AV, Babu S, Berry JD, Cudkowicz ME, Paganoni S. Yerton M, et al. Among authors: berry jd. Muscle Nerve. 2023 Jun;67(6):456-463. doi: 10.1002/mus.27819. Epub 2023 Apr 5. Muscle Nerve. 2023. PMID: 36929648
Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: subgroup analysis of demographic and clinical characteristics.
Rudnicki SA, Berry JD, Ingersoll E, Archibald D, Cudkowicz ME, Kerr DA, Dong Y. Rudnicki SA, et al. Among authors: berry jd. Amyotroph Lateral Scler Frontotemporal Degener. 2013 Jan;14(1):44-51. doi: 10.3109/17482968.2012.723723. Epub 2012 Sep 17. Amyotroph Lateral Scler Frontotemporal Degener. 2013. PMID: 22985432 Clinical Trial.
Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis.
Berry JD, Shefner JM, Conwit R, Schoenfeld D, Keroack M, Felsenstein D, Krivickas L, David WS, Vriesendorp F, Pestronk A, Caress JB, Katz J, Simpson E, Rosenfeld J, Pascuzzi R, Glass J, Rezania K, Rothstein JD, Greenblatt DJ, Cudkowicz ME; Northeast ALS Consortium. Berry JD, et al. PLoS One. 2013 Apr 17;8(4):e61177. doi: 10.1371/journal.pone.0061177. Print 2013. PLoS One. 2013. PMID: 23613806 Free PMC article. Clinical Trial.
Neuroprotective agents target molecular mechanisms of disease in ALS.
Zhu Y, Fotinos A, Mao LL, Atassi N, Zhou EW, Ahmad S, Guan Y, Berry JD, Cudkowicz ME, Wang X. Zhu Y, et al. Among authors: berry jd. Drug Discov Today. 2015 Jan;20(1):65-75. doi: 10.1016/j.drudis.2014.08.016. Epub 2014 Sep 6. Drug Discov Today. 2015. PMID: 25205348 Review.
396 results